Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Acute Iron Intoxication Condition: Patients not in shock |
Dose: Intramuscular Administration – 1000 mg Frequency: initially Note: This route is preferred and should be used for all patients not in shock. |
|
Indication: Acute Iron Intoxication Condition: Patients not in shock |
Dose: Intramuscular Administration – 500 mg Frequency: every 4 hours for two doses Note: This follows the initial 1000 mg dose. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Acute Iron Poisoning Age: less than 3 years |
Dose: Injection – Safety and effectiveness has not been established Note: Safety and effectiveness has not been established |
|
Indication: Acute Iron Poisoning Age: greater than 3 years Condition: patients not in shock |
Dose: Intramuscular – 1 g initially and then 500 mg Frequency: initial dose then every 4 hours for 2 doses Note: maximum dose: 6 g in 24 hours; depending upon clinical response, subsequent doses of 500 mg every 4-12 hours can be administered |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment |
Dose: Not mentioned Note: Use with caution. |
Administration
- Can be given IM, IV, or SC
- Use immediately after reconstitution
Side Effect
- localized irritation
- induration
- infiltration
- pain
- erythema
- wheal formation
- eschar
- burning
- swelling
- pruritus
- crust
- vesicles
- arthralgia
- asthma
- fever
- headache
- myalgia
- nausea
- vomiting
- tachycardia
- shock
- angioedema
- generalized rash
- urticaria
- diarrhea
- nausea
- vomiting
- hepatic dysfunction
- growth retardation and bone changes including metaphyseal dysplasia are common in doses ≥ 60 mg/kg
- especially those who begin iron chelation in the first three years of life, reduced risk if doses are kept to ≤ 40 mg/kg
- peripheral sensory, motor or mixed neuropathy
- paresthesias
- seizures
- high-frequency sensorineural hearing loss and/or tinnitus are uncommon if dosage guidelines are not exceeded and if dose is reduced when ferritin levels decline
- visual disturbances inlcuding decreased acuity
- blurred vision
- loss of vision
- dyschromatopsia
- night blindness
- visual field defects
- scotoma
- retinopathy (pigmentary degeneration)
- optic neuritis
- cataracts are rare if dosage guidelines are not exceeded
- acute respiratory distress syndrome with dyspnea
- cyanosis and/or interstitial infiltrates
- Very rare generalized rash
- dysuria
- acute renal failure
- increased serum creatinineeatinine and renal tubular disorders
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Vitamin C
|
May enhance iron toxicity
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Severe Renal Disease
|
Risk of kidney complications
|
|
Anuria
|
Can worsen kidney failure
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store between 15-25 °C. Do not store above 25°C.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.